Studies on Hepatitis Viruses

Studies on Hepatitis Viruses PDF Author: Satya Prakash Gupta
Publisher: Academic Press
ISBN: 0128133317
Category : Medical
Languages : en
Pages : 244

Get Book Here

Book Description
Studies on Hepatitis Viruses: Life Cycle, Structure, Functions, and Inhibition presents the latest on this systemic infection that predominantly affects the liver with inflammation that can be acute or chronic. Hepatitis viruses have been the subject of intense study in the last twenty years, with a wealth of information related to their lifecycle, structure, functions and inhibition being presented. This book compiles the most important developments and research, giving users a very useful guide on this evolving area of virology and medicinal chemistry. - Provides comprehensive, state-of-the-art coverage of hepatitis virus infections, the virus' lifecycle, and mechanisms of protease inhibition - Analyzes structure-activity relationships of inhibitors of viral hepatitis - Presents an in-depth view of the structure and function of viral hepatitis - Discusses classification, epidemiology, pathogenesis, natural history, clinical manifestations, diagnosis, complications, associated disorders and animal models

Studies on Hepatitis Viruses

Studies on Hepatitis Viruses PDF Author: Satya Prakash Gupta
Publisher: Academic Press
ISBN: 0128133317
Category : Medical
Languages : en
Pages : 244

Get Book Here

Book Description
Studies on Hepatitis Viruses: Life Cycle, Structure, Functions, and Inhibition presents the latest on this systemic infection that predominantly affects the liver with inflammation that can be acute or chronic. Hepatitis viruses have been the subject of intense study in the last twenty years, with a wealth of information related to their lifecycle, structure, functions and inhibition being presented. This book compiles the most important developments and research, giving users a very useful guide on this evolving area of virology and medicinal chemistry. - Provides comprehensive, state-of-the-art coverage of hepatitis virus infections, the virus' lifecycle, and mechanisms of protease inhibition - Analyzes structure-activity relationships of inhibitors of viral hepatitis - Presents an in-depth view of the structure and function of viral hepatitis - Discusses classification, epidemiology, pathogenesis, natural history, clinical manifestations, diagnosis, complications, associated disorders and animal models

A National Strategy for the Elimination of Hepatitis B and C

A National Strategy for the Elimination of Hepatitis B and C PDF Author: National Academies of Sciences, Engineering, and Medicine
Publisher: National Academies Press
ISBN: 0309457297
Category : Medical
Languages : en
Pages : 297

Get Book Here

Book Description
Hepatitis B and C cause most cases of hepatitis in the United States and the world. The two diseases account for about a million deaths a year and 78 percent of world's hepatocellular carcinoma and more than half of all fatal cirrhosis. In 2013 viral hepatitis, of which hepatitis B virus (HBV) and hepatitis C virus (HCV) are the most common types, surpassed HIV and AIDS to become the seventh leading cause of death worldwide. The world now has the tools to prevent hepatitis B and cure hepatitis C. Perfect vaccination could eradicate HBV, but it would take two generations at least. In the meantime, there is no cure for the millions of people already infected. Conversely, there is no vaccine for HCV, but new direct-acting antivirals can cure 95 percent of chronic infections, though these drugs are unlikely to reach all chronically-infected people anytime soon. This report, the second of two, builds off the conclusions of the first report and outlines a strategy for hepatitis reduction over time and specific actions to achieve them.

Guidelines on Hepatitis B and C Testing

Guidelines on Hepatitis B and C Testing PDF Author: World Health Organization
Publisher: World Health Organization
ISBN: 9789241549981
Category : Medical
Languages : en
Pages : 0

Get Book Here

Book Description
Testing and diagnosis of hepatitis B (HBV) and C (HCV) infection is the gateway for access to both prevention and treatment services, and is a crucial component of an effective response to the hepatitis epidemic. Early identification of persons with chronic HBV or HCV infection enables them to receive the necessary care and treatment to prevent or delay progression of liver disease. Testing also provides an opportunity to link people to interventions to reduce transmission, through counselling on risk behaviors and provision of prevention commodities (such as sterile needles and syringes) and hepatitis B vaccination. These are the first WHO guidelines on testing for chronic HBV and HCV infection and complement published guidance by WHO on the prevention, care and treatment of chronic hepatitis C and hepatitis B infection. These guidelines outline the public health approach to strengthening and expanding current testing practices for HBV and HCV, and are intended for use across age groups and populations.

Hepatitis B Virus

Hepatitis B Virus PDF Author: Haitao Guo
Publisher: Springer Nature
ISBN: 1071640275
Category :
Languages : en
Pages : 278

Get Book Here

Book Description


Hepatitis and Liver Cancer

Hepatitis and Liver Cancer PDF Author: Institute of Medicine
Publisher: National Academies Press
ISBN: 0309153689
Category : Medical
Languages : en
Pages : 252

Get Book Here

Book Description
The global epidemic of hepatitis B and C is a serious public health problem. Hepatitis B and C are the major causes of chronic liver disease and liver cancer in the world. In the next 10 years, 150,000 people in the United States will die from liver disease or liver cancer associated with chronic hepatitis B virus (HBV) or hepatitis C virus (HCV) infections. Today, between 800,000 and 1.4 million people in the United States have chronic hepatitis B and between 2.7 and 3.9 million have chronic hepatitis C. People most at risk for hepatitis B and C often are the least likely to have access to medical services. Reducing the rates of illness and death associated with these diseases will require greater awareness and knowledge among health care workers, improved identification of at-risk people, and improved access to medical care. Hepatitis B is a vaccine-preventable disease. Although federal public health officials recommend that all newborns, children, and at-risk adults receive the vaccine, about 46,000 new acute cases of the HBV infection emerge each year, including 1,000 in infants who acquire the infection during birth from their HBV-positive mothers. Unfortunately, there is no vaccine for hepatitis C, which is transmitted by direct exposure to infectious blood. Hepatitis and Liver Cancer identifies missed opportunities related to the prevention and control of HBV and HCV infections. The book presents ways to reduce the numbers of new HBV and HCV infections and the morbidity and mortality related to chronic viral hepatitis. It identifies priorities for research, policy, and action geared toward federal, state, and local public health officials, stakeholder, and advocacy groups and professional organizations.

Eliminating the Public Health Problem of Hepatitis B and C in the United States

Eliminating the Public Health Problem of Hepatitis B and C in the United States PDF Author: National Academies of Sciences, Engineering, and Medicine
Publisher: National Academies Press
ISBN: 0309438020
Category : Medical
Languages : en
Pages : 187

Get Book Here

Book Description
Hepatitis B and C cause most cases of hepatitis in the United States and the world. The two diseases account for about a million deaths a year and 78 percent of world's hepatocellular carcinoma and more than half of all fatal cirrhosis. In 2013 viral hepatitis, of which hepatitis B virus (HBV) and hepatitis C virus (HCV) are the most common types, surpassed HIV and AIDS to become the seventh leading cause of death worldwide. The world now has the tools to prevent hepatitis B and cure hepatitis C. Perfect vaccination could eradicate HBV, but it would take two generations at least. In the meantime, there is no cure for the millions of people already infected. Conversely, there is no vaccine for HCV, but new direct-acting antivirals can cure 95 percent of chronic infections, though these drugs are unlikely to reach all chronically-infected people anytime soon. This report, the first of two, examines the feasibility of hepatitis B and C elimination in the United States and identifies critical success factors. The phase two report will outline a strategy for meeting the elimination goals discussed in this report.

Viral Hepatitis Molecular Biology Diagnosis and Control

Viral Hepatitis Molecular Biology Diagnosis and Control PDF Author: Isa K. Mushahwar
Publisher: Gulf Professional Publishing
ISBN: 9780444514875
Category : Medical
Languages : en
Pages : 298

Get Book Here

Book Description
The last forty years have witnessed the discovery of five human hepatitis viruses: hepatitis virus A, B, C, D, and E, and two related blood-borne viruses: GB virus C and TT virus. Viral Hepatitis provides a comprehensive overview of the latest developments and research studies in human viral hepatitis. Written by leading international scientists in the field, this book covers topics ranging from the history of these viruses to their molecular biology, diagnosis, epidemiology and control. It will be an invaluable reference source for hepatitis researchers, reference and diagnostic laboratories, clinicians, public health officers and graduate and medical students. Book jacket.

Review of the Fialuridine (FIAU) Clinical Trials

Review of the Fialuridine (FIAU) Clinical Trials PDF Author: Institute of Medicine
Publisher: National Academies Press
ISBN: 0309176611
Category : Medical
Languages : en
Pages : 279

Get Book Here

Book Description
In June 1993 a clinical trial of fialuridine (FIAU), a promising new medication for hepatitis B, was abruptly terminated when one of the 15 out-patients participating in the National Institutes of Health (NIH) study was suddenly hospitalized with liver failure. Although all the remaining patients were contacted and told to stop taking their medication, six more subsequently developed severe toxicity. Five patients died, and two others were probably saved from death only by having liver transplants. In response to a request from the Secretary of the Department of Health and Human Services, the IOM committee has analyzed the FIAU clinical trials, making recommendations for additional safeguards for the conduct of future clinical trials. This evaluation included the review of documents pertaining to investigational new drug submissions, protocols and consent forms from other clinical trials, as well as information available from other clinical and preclinical experience with compounds related to FIAU and its parent drug, fiacitibine (FIAC), which is metabolized to FIAU. The committee does not seek to affix responsibility for the adverse outcome of this NIH trial, but instead focuses on whether any rules or procedures governing the clinical trials process itself need to be changed, and if so, what burdens or costs such changes might place on future clinical trials.

Adverse Effects of Vaccines

Adverse Effects of Vaccines PDF Author: Institute of Medicine
Publisher: National Academies Press
ISBN: 0309214351
Category : Medical
Languages : en
Pages : 894

Get Book Here

Book Description
In 1900, for every 1,000 babies born in the United States, 100 would die before their first birthday, often due to infectious diseases. Today, vaccines exist for many viral and bacterial diseases. The National Childhood Vaccine Injury Act, passed in 1986, was intended to bolster vaccine research and development through the federal coordination of vaccine initiatives and to provide relief to vaccine manufacturers facing financial burdens. The legislation also intended to address concerns about the safety of vaccines by instituting a compensation program, setting up a passive surveillance system for vaccine adverse events, and by providing information to consumers. A key component of the legislation required the U.S. Department of Health and Human Services to collaborate with the Institute of Medicine to assess concerns about the safety of vaccines and potential adverse events, especially in children. Adverse Effects of Vaccines reviews the epidemiological, clinical, and biological evidence regarding adverse health events associated with specific vaccines covered by the National Vaccine Injury Compensation Program (VICP), including the varicella zoster vaccine, influenza vaccines, the hepatitis B vaccine, and the human papillomavirus vaccine, among others. For each possible adverse event, the report reviews peer-reviewed primary studies, summarizes their findings, and evaluates the epidemiological, clinical, and biological evidence. It finds that while no vaccine is 100 percent safe, very few adverse events are shown to be caused by vaccines. In addition, the evidence shows that vaccines do not cause several conditions. For example, the MMR vaccine is not associated with autism or childhood diabetes. Also, the DTaP vaccine is not associated with diabetes and the influenza vaccine given as a shot does not exacerbate asthma. Adverse Effects of Vaccines will be of special interest to the National Vaccine Program Office, the VICP, the Centers for Disease Control and Prevention, vaccine safety researchers and manufacturers, parents, caregivers, and health professionals in the private and public sectors.

Hepatitis B

Hepatitis B PDF Author: Baruch S. Blumberg
Publisher: Princeton University Press
ISBN: 9780691116235
Category : Biography & Autobiography
Languages : en
Pages : 274

Get Book Here

Book Description
About 375 million people are infected with the hepatitis B virus. It has killed more people than AIDS and also causes millions of cases of liver cancer. The discovery of this deadly virus and the vaccine against it--a vaccine that is sharply decreasing the infection rate worldwide and is probably the first effective cancer vaccine--was one of the great triumphs of twentieth-century medicine. And it almost didn't happen. With wit and insight, this scientific memoir and story of discovery describes how Baruch Blumberg and a team of researchers found a virus they were not looking for and created a vaccine for a disease they previously knew little about--work that took the author around the world and won him the Nobel Prize. Blumberg and his collaborators were investigating relationships between gene distribution and disease susceptibility, research that was yielding interesting data but no real breakthroughs. Many viewed their work as more field trip than science. But, through decades of hard work and investigative twists and turns, their pursuit led to the hepatitis B antigen, the elusive virus itself, and, ultimately, the vaccine. As he takes the reader through the detective work that culminated in his incredible discovery, the author recounts with immediacy exciting moments in the lab and in the field--from a hair-raising flight to Africa to an unpleasant encounter with Alaskan sled dogs. The hepatitis B story is more than a fascinating chronicle of a major discovery. What Blumberg followed to the virus was a trail of remarkable "accidents" that happen when scientists seek answers to interesting questions. Those events, combined with the investigator's determined persistence, resulted in studies that generated a pharmaceutical industry, have far-flung public-health applications, and saved millions of lives.